IMVT as reported
Immunovant, Inc. reported $25M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.
$25M
Revenue, trailing twelve months · to Q4 2024 · every figure below is as filed, with no scoring applied
- Net Income
- −$538M
Net Income · +20% year on year · trailing twelve months to Q1 2027
- Free Cash Flow
- −$407M
Free Cash Flow · trailing twelve months to Q4 2026
- EPS
- −$2.82
EPS · −0.70% year on year · trailing twelve months to Q1 2027
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $25M | n/a | Q4 2024 · 9 quarters behind |
| Net Income | −$538M | +20% | Q1 2027 |
| EPS | −$2.82 | −0.70% | Q1 2027 |
| Op Margin | −1229% | n/a | Q4 2024 · 9 quarters behind |
| Net Margin | −1234% | n/a | Q4 2024 · 9 quarters behind |
| ROE | −67% | n/a | Q1 2027 |
| ROA | −60% | n/a | Q1 2027 |
| Free Cash Flow | −$407M | n/a | Q4 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Immunovant, Inc. (IMVT) - Revenue & ProfitRevenue & ProfitImmunovant, Inc. (IMVT)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com